CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
FIDA is a novel platform for immunological measurements that simplifies and standardizes the process of quantifying antibodies under native conditions. It aims to improve vaccine research and reduce costs associated with antibody testing by providing faster and more sensitive assays.
Therapeutic antibodies have rapidly become a major component of modern medicine.
The global research antibodies market size is expected to reach €3.8bn by 2025.
However, exiting research tools have not been able to eliminate Hyper-Sensitivity Reactions (HSRs) against the biologic drug by the patient’s immune system. HSRs are estimated to occur in 10-15% of hospital patients and can arise for any biologic, mostly antibodies.Antibodies are also important in the R&D of new vaccines.
To test vaccine…
FIDA BIOSYSTEMS APS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Paris
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Switzerland, Windisch
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Paris
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
